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Introduction: Pemetrexed is effective in the treatment of non–
small-cell lung cancer, mainly in nonsquamous cell carcinomas. 
Inhibition of thymidylate synthase (TS) is considered the key mecha-
nism of action. Folate receptor-α facilitates uptake of pemetrexed. 
Polyglutamation by folylpolyglutamate synthetase enhances activity 
and prolongs cellular retention of pemetrexed. Thyroid transcription 
factor-1 (TTF-1) is mainly positive in nonsquamous cell carcinoma 
and has been proposed as a marker for sensitivity to pemetrexed. 
The aim was to investigate associations between these biomarkers 
and survival in patients who participated in a phase III trial compar-
ing pemetrexed plus carboplatin with gemcitabine plus carboplatin 
as first-line chemotherapy in advanced non–small-cell lung cancer 
(n = 436). In this study, there was no difference in overall survival 
between the two regimens.
Methods: Formalin-fixed, paraffin-embedded biopsies were col-
lected. Percentages of tumor cells positive and highly positive for the 
biomarkers were assessed using immunohistochemistry (IHC) and 
an IHC score was calculated (range, 0–200).
Results: Two hundred thirty-six biopsies were analyzed (pemetrexed 
plus carboplatin: n = 114, gemcitabine plus carboplatin: n = 122). 
There was a significant difference in overall survival between those 
with TTF-1–positive and –negative tumors (10.4 versus 6.0 months; 
p < 0.001) and those with a low and a high TS IHC score (9.7 ver-
sus 6.2 months; p < 0.001). Folate receptor-α and folylpolyglutamate 
synthetase were not significant prognostic factors. In multivariate 
analyses adjusting for established prognostic characteristics, TS 
(p = 0.002) and TTF-1 (p = 0.003) remained significant. There were 
no differences in survival between the treatment arms depending on 
biomarker scores.
Conclusions: TTF-1 positivity and low TS level were associated 
with prolonged survival. The associations between the biomarkers 
and overall survival were similar for both chemotherapy regimens.
Key Words: Non-small-cell lung cancer, Biomarkers, Pemetrexed, 
Gemcitabine, Survival, Thyroid transcription factor-1, Thymidylate 
synthase, Folylpolyglutamate synthetase, Folate receptor.
(J Thorac Oncol. 2013;8: 1255-1264)
Platinum-doublet chemotherapy remains the standard treat-ment for most patients with advanced non–small-cell lung 
cancer (NSCLC).1 However, the survival benefit is limited, and 
many experience severe side effects.2 Identifying biomarkers 
that are associated with outcomes of specific regimens would 
help improve efficacy and avoid ineffective, potentially harm-
ful therapy.
Pemetrexed is a multitargeted antifolate that inhibits 
three enzymes in the folate pathway involved in nucleotide 
synthesis; thymidylate synthase (TS), dihydrofolate reductase, 
and glycinamide ribonucleotide formyl transferase. Studies 
have demonstrated that pemetrexed is effective as first-line,3,4 
second-line,5 and maintenance therapy of NSCLC.6,7 Subgroup 
analyses have revealed that the agent is mainly effective and 
superior to other regimens in nonsquamous cell carcinomas 
(non-SCCs).6,8
Inhibition of TS is thought to be the main mechanism 
of action.9 In cell lines from colon and lung cancer, resistance 
to pemetrexed was associated with TS overexpression.10–13 In 
patients with malignant mesothelioma,14,15 breast cancer,16 
and NSCLC,17–20 low TS levels were associated with a better 
response to pemetrexed. Others have found that SCCs have 
higher TS levels than non-SCCs and that TS levels in small-
cell lung cancer are higher than in NSCLC.21–23 It has been 
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hypothesized that this explains why non-SCCs are more sen-
sitive to pemetrexed than SCCs,21,22 and why most small-cell 
lung cancers are resistant to pemetrexed.24,25
Folate receptor-α (FR-α) mediates cellular uptake of 
folate essential for synthesis of RNA and DNA, may facili-
tate transport of pemetrexed into cells, and has been proposed 
as a biomarker for antifolate therapy.26,27 Folylpolyglutamate 
synthetase (FPGS) activates pemetrexed via polyglutamation 
and prolongs its cellular retention. Low levels of FPGS may 
thereby decrease the antitumor activity. A study of leukemia 
cells suggested that low FPGS level was associated with resis-
tance to pemetrexed.28
Thyroid transcription factor-1 (TTF-1) is mainly 
expressed in non-SCC and is an important marker for subclas-
sification of NSCLC when no clear morphologic features can 
be found.29 In one study, TTF-1 positive tumors had higher 
response rates to pemetrexed than TTF-1 negative,18 and it has 
been proposed that the biomarker can explain why pemetrexed 
is mainly active in non-SCC.
Gemcitabine is one of the standard therapies of 
NSCLC.30 It is a pyrimidine-analogue that inhibits DNA syn-
thesis by inducing depletion of cellular deoxynucleotides and 
through incorporation into DNA.31
Our study group conducted a phase III trial compar-
ing pemetrexed plus carboplatin (PC) with gemcitabine plus 
carboplatin (GC) as first-line chemotherapy in advanced 
NSCLC.3 The aim of this study was to investigate associations 
between TTF-1, TS, FR-α, or FPGS and overall survival in 
participants of this trial, and to determine whether there were 
different associations between these biomarkers and overall 
survival between the two treatment arms.
MATERIALS AND METHODS
The main eligibility criteria for the phase III trial were 
stage IIIB (ineligible for curative radiotherapy) or stage IV 
NSCLC; no previous chemotherapy; age ≥18 years; and World 
Health Organization performance status (PS) 0 to 2. Patients 
received up to four cycles of carboplatin area under the 
curve = 5 (Calvert’s formula) plus pemetrexed 500 mg/m2 day 
1 (PC) or carboplatin area under the curve = 5 day 1 plus gem-
citabine 1000 mg/m2 days 1 and 8 (GC) every 3 weeks. Four 
hundred thirty-six eligible patients were enrolled from May 
2005 until July 2006 at 35 hospitals in Norway. The survival 
analyses were finalized in July 2007 after a median observa-
tion time of 19 months. The main conclusions were that there 
were no differences in health-related quality of life or overall 
survival between the arms. More hematological toxicity was 
observed on the gemcitabine arm.3
Patients were included in the present study if we were 
able to collect formalin-fixed, paraffin-embedded tumor tissue 
for immunohistochemicial analyses.
Design and Approval
This retrospective biomarker study was approved by the 
Regional Committee for Medical Research Ethics, Central 
Norway; the Norwegian Social Science Data Services; and the 
Norwegian Directorate for Health and Social Affairs.
Immunohistochemical Assays
Tissue micro arrays were built of one to three cores 
(1-mm diameter) from the tumor samples when possible. 
Otherwise, sections were cut from the whole remaining tissue 
blocks. Sections, cut at 4 µm, were positioned on Superfrost 
Plus slides (Menzel-Glaser, Braunschweig, Germany) and 
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FIGURE 1.  Patient selection for the biomarker study. TS, thymidylate synthase; TTF-1, thyroid transcription factor-1; FR, folate 
receptor; FPGS, folylpolyglutamate synthetase; NSCLC, non–small-cell lung cancer; TMAs, tissue micro arrays.
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deparaffinized. Ventana’s Bench Mark XT staining plat-
form was used for immunohistochemistry (IHC). Antigen 
retrieval was conducted under standard conditions with cell 
conditioning 1 (CC1) buffer (VMSI, Tucson, AZ; Catalog 
No 950-124). Slides were incubated with the appropriate 
dilution of the primary antibody for 1 hour at room tem-
perature. The antibodies to TS, FR-α, and FPGS were non-
commercial murine monoclonal antibodies from Eli Lilly & 
Co. (Indianapolis, IN); the monoclonal anti–TTF-1 was from 
Ventana Medical Systems (VMSI; Catalog No 760–2829). 
As a negative control, specimens were incubated with mouse 
immunoglobulin under the same conditions. Sections from a 
paraffin-embedded, carcinoma specimen, earlier tested and 
found positive for the markers by Ventana Medical Systems, 
were used as positive controls—one section for each marker 
in each run. Binding of primary antibodies to the tissue 
samples was detected using the Ultra View detection kit 
(VMSI; Catalog No 760-500). Enzymatic detection was 
accomplished with a streptavidin horseradish peroxidase 
conjugate, followed by reaction with hydrogen peroxide in 
the presence of diamino benzidine and copper sulfate.
Scoring
Three pathologists (MLI, HS, and EHS) scored the 
slides. All pathologists underwent training by a pathologist 
from—and scored the slides as recommended by—the com-
pany that developed the immunoassays (Dr. Eric Powell; 
Ventana Medical Systems Inc.). All pathologists individu-
ally scored 10% of the samples for all biomarkers. Because 
of very high interrater reliability, the slides were shared, and 
the rest of the slides for each marker were scored by one of 
the three pathologists. An intensity identified as higher than 
background and specific for the cells of interest was scored as 
1+. Staining with an intensity that allowed detection of posi-
tive tumor cells at low magnification (40×) was scored as 2+. 
Percentages of negative (0), positive (1+), and highly positive 
(2+) tumor cells in each sample were assessed. An IHC score 
was calculated for each marker on each sample: IHC score = 
([% of 1+] × 1) + ([% of 2+] × 2) providing a range of 0 to 
200. We were not able to accurately distinguish between FR 
expression in the cytoplasm and in the membrane. When more 
than one sample from one biopsy was analyzed, the average 
IHC score was used in the analyses.
Statistical Considerations
Survival was defined as time from random assignment 
until death and was estimated using the Kaplan–Meier method. 
Survival data were compared using the log-rank test. The Cox 
proportional hazards method was used to calculate hazard 
ratios (HRs). The ANOVA test was used to compare IHC scores 
between the different histological subgroups. In the comparative 
biomarker analyses, we used the median IHC score as a cutoff 
point. Furthermore, we compared the lower and upper quartiles; 
tumors with any positive versus all negative cells; and tumors 
with any highly positive cells versus the others. Interaction tests 
were performed to investigate whether any combinations of 
biomarkers were associated with differences in overall survival. 
Because the use of platinum-doublet chemotherapy is debated 
in PS 2 patients, all the analyses were also separately conducted 
for patients with PS of 0 to 1. Statistical significance level was 
defined as p value less than 0.05.
RESULTS
Patients
The NSCLC diagnosis was confirmed histologically in 
370 patients. We were able to retrieve paraffin blocks from 
336 of these. In 97 cases, there was not enough tumor tis-
sue for IHC analyses, and in three cases, a central pathology 
review revealed other cancer than NSCLC. Thus, a total of 
236 patients were included in the present study. In 65 cases, 
there was sufficient tissue to build tissue micro arrays. We 
were not able to analyze all samples for all four biomarkers; 
TABLE 1.  Baseline Characteristics of the Patients Included in 
the Biomarker Study
Carboplatin/
Pemetrexed
(n = 114)
Carboplatin/
Gemcitabine
(n = 122)
n % n %
Age Median 62 64
Range 35–85 37–81
Sex Men 60 53 66 54
Women 54 47 56 46
Stage IIIB 36 32 39 32
IV 78 68 83 68
Performance 
status
0 28 25 22 18
1 60 53 68 56
2 26 23 32 26
Histology Adenocarcinoma 52 46 60 49
Squamous cell  
carcinoma
31 27 31 25
Large-cell carcinoma 6 5 7 6
Other 25 22 24 20
Smoking history Never smoker 11 10 7 6
Former smoker 61 54 64 53
Current smoker 42 37 51 42
Cycles of 
chemotherapy
Mean 3.2 3.1
Any systemic  
second-line  
therapy
39 34 36 30
Docetaxel 14 12 11 9
Reinduction 2 2 7 6
Pemetrexed 2 2 3 3
Carboplatin/ 
vinorelbine
4 4 5 4
Erlotinib 12 11 9 7
Vinorelbine 2 2 - -
Other 3 3 1 1
Any systemic  
third-line  
therapy
5 4 8 7
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222 were analyzed for TS; 228 for TTF-1; 215 for FR-α; and 
221 for FPGS (Fig. 1).
Median age of the patients was 63 years (range, 35–85); 
53% were men; 32% had stage IIIB; 75% had PS 0 to 1; 8% 
were never-smokers; 48% received PC, 52% GC. The baseline 
characteristics, number of cycles of chemotherapy adminis-
tered, and the use of poststudy systemic cancer therapy were 
similar in the two treatment arms (Table 1).
Tumor Samples
The biopsies were collected from the lung or medias-
tinum in 86% of the patients; from lymph node metastases 
from the neck or supraclavicular region in 6%; from bone 
metastases in 4%; from liver, pleura, brain, adrenal gland, or 
other lymph nodes in the remaining 4%. The biopsy samples 
were collected through bronchoscopy in 48% of the patients; 
percutaneous biopsy in 28%; surgery in 20% (approximately 
half of these patients had primary surgery and were enrolled 
when they developed advanced disease; in the other cases, a 
biopsy sample was collected through surgery), and mediasti-
noscopy in 4%.
Biomarker Status
The distributions of IHC scores are shown in Figure 2. 
Among the biopsy samples, 47% (111 of 228) was TTF-1 
positive; 42% (100 of 228) had 2+ tumor cells; the median 
IHC score was 0 (SD: 78). Ninety-three percent (219 of 223) 
was TS positive; 89% (211 of 222) had 2+ tumor cells, and 
the median IHC score was 134 (SD: 45). Fifty-six percent 
(131 of 215) was FR-α positive; 17% (41 of 215) had 2+ 
tumor cells, and the median IHC score was 10 (SD: 40). 
Ninety-two percent (219 of 221) was FPGS positive; 57% 
(134 of 222) had 2+ tumor cells, and the median IHC score 
was 100 (SD: 61).
The percentages of FPGS 2+ and TTF-1 positive tumors 
were significantly lower among SCCs (p < 0.001). Six cases 
originally diagnosed as SCCs were TTF-1 positive. There 
were no significant differences in the percentages of TS 1+ 
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FIGURE 2.  Distribution of immunohistochemistry (IHC) scores for all samples. IHC score = (% 1 + positive tumor cells × 1) +  
(% 2 + positive tumor cells × 2). Range, 0 to 200. TS, thymidylate synthase; TTF-1, thyroid transcription factor-1; FR, folate 
receptor; FPGS, folylpolyglutamate synthetase.
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(p = 0.62), TS 2+ (p = 0.35), FR-α 1+ (p = 0.16), FR-α 2+ 
(p = 0.07), or FPGS 1+ (p = 0.19) tumors among the histologi-
cal subgroups.
The median IHC scores for TS (p = 0.51) or FR-α  
(p = 0.08) were not different among the histological sub-
groups, nor were there any differences in TS level when 
comparing SCCs with adenocarcinomas plus TTF-1–positive 
large-cell and other carcinomas (p = 0.30). The median IHC 
scores of TTF-1 (p < 0.001) and FPGS (p = 0.001) were sig-
nificantly lower in SCCs compared with those of the other 
subgroups (Fig. 3).
Overall Survival
Results from the univariate survival analyses are 
shown in Table 2, and a selection of survival curves are 
shown in Figure 4. Patients with a TS IHC score below the 
median value had a longer survival than those with a higher 
TS IHC score (9.7 versus 6.2 months; p = 0.002). Those with 
TTF-1–positive tumors had a significantly longer overall 
survival than those with TTF-1–negative tumors (10.4 ver-
sus 6.0 months; p < 0.001). The exclusion of patients with 
SCC who received pemetrexed did not change the prognostic 
value of TS or TTF-1 (data not shown). There were no sig-
nificant differences in survival when comparing those with 
an FR IHC score over/under the median value (8.4 versus 6.5 
months; p = 0.33), but there was a trend to prolonged sur-
vival for those with an IHC score in the upper quartile when 
compared with those in the lowest quartile (10.1 versus 6.3 
months; p = 0.075). There were no significant differences in 
overall survival depending on FPGS IHC scores. Interaction 
tests revealed that those with TTF-1–positive tumors and a 
TS IHC score below the median value had a significantly 
longer overall survival than the other patients (12.9 versus 
6.3 months; p < 0.001).
There was no difference in overall survival between 
SCCs or nonsquamous (adenocarcinomas and large-cell 
TS
 IH
C-
Sc
or
e
200
150
100
50
0
Squamous Adeno Large cell Other
Squamous Adeno Large cell Other
Squamous Adeno Large cell Other
Squamous Adeno Large cell Other
TT
F1
 IH
C-
Sc
or
e
200
150
100
50
0
FR
 IH
C-
Sc
or
e
200
150
100
50
0
FP
G
S 
IH
C-
Sc
or
e
200
150
100
50
0
FIGURE 3.  IHC scores split for histological subgroups. The box plots show minimum, first quartile, median, third quartile, and 
maximum values. IHC, immunohistochemistry; TS, thymidylate synthase; TTF-1, thyroid transcription factor-1; FR, folate recep-
tor; FPGS, folylpolyglutamate synthetase.
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carcinomas) in the overall population (7.3 versus 7.1 months; 
p = 0.31); among those who received pemetrexed (n = 91; 7.4 
versus 6.8 months; p = 0.64); those who received gemcitabine 
(n = 99; 6.5 versus 7.1 months; p = 0.32); among those with a 
TS IHC score that was equal to or more than the median value 
(n = 97; 6.6 versus 5.0 months; p = 0.64); TS less than median 
(n = 88; 9.4 versus 11.0; p = 0.32); TTF-1 positive (n = 88; 9.4 
versus 10.8 months; p = 0.87); TTF-1 negative (n = 97; 7.0 
versus 5.0 months; p = 0.20); FR ≥ median (n = 89; 7.4 versus 
8.8 months; p = 0.20); FR less than median (n = 89; 6.7 versus 
6.4; p = 0.95); FPGS equal to or more than median (n = 83; 
7.2 versus 7.4 months; p = 0.09); or FPGS less than median 
(n = 95; 7.0 versus 6.8; p = 0.77).
PS, use of second-line systemic therapy, and appetite 
loss at baseline were significant prognostic factors in the uni-
variate analyses. Multivariate analyses adjusting for these 
factors as well as the other significant prognostic characteris-
tics in the main study (stage of disease, sex, global quality of 
life, and appetite loss at baseline)3,32 revealed that use of sec-
ond-line therapy (HR = 0.48; 95% confidence interval [CI], 
0.34–0.69), appetite loss (HR = 0.63; 95% CI, 0.46–0.86), 
TTF-1 (HR = 0.71; 95% CI, 0.52–0.97), and TS IHC scores 
(HR = 0.59; 95% CI, 0.44–0.80) remained significant prog-
nostic factors. When including the interaction tests, TTF-1 
positivity/low TS turned out to be the strongest prognostic 
biomarker (HR = 0.68; 95% CI, 0.57–0.81).
There were no differences in overall survival between 
the treatment arms among those with a low (HR = 1.01; 95% 
CI, 0.64–1.57) or high (HR = 0.93; 95% CI, 0.64–1.38) TS 
IHC score; those with TTF-1–positive (HR = 1.10; 95% 
CI, 0.71–1.69) or –negative tumors (HR = 0.85; 95% CI, 
0.58–1.25); high (HR = 0.82; 95% CI, 0.53–1.23) or low 
(HR = 1.15; 95% CI, 0.76–1.73) FR-α-score or high 
(HR = 0.82; 95% CI, 0.53–1.23) or low (HR = 1.07; 95% CI, 
0.72–1.59) FPGS-score (Fig. 5). Nor were there any different 
associations between these biomarkers and overall survival 
between the treatments arms when using other cutpoints for 
the IHC analyses, in interaction tests, when analyzing patients 
with PS 0 to 1 separately or when analyzing those who never 
received any systemic cancer therapy after completing the 
study treatment.
DISCUSSION
Low tumor TS level and TTF-1-positive tumors were 
significant positive prognostic factors for survival in our study 
population of patients with advanced NSCLC. Interaction 
tests revealed that the combination of low TS and TT1 posi-
tivity was the strongest prognostic biomarker score. FR and 
FPGS were not significant prognostic factors, and there were 
no differences in associations between the four biomarkers 
and overall survival between the two treatment arms.
Patients with low tumor TS level had a longer survival 
than those with a high tumor TS level in the PC arm. But this 
was also the case in the GC arm, and there were no differ-
ences in survival between the treatment arms depending on 
any TS scores. Possible explanations are that TS is a prog-
nostic factor for survival in NSCLC in general, in patients 
with advanced NSCLC receiving chemotherapy, or that TS 
level predicts sensitivity to both of the regimens adminis-
tered in our trial.
Our results are in accordance with several other reports. 
Low TS has been associated with lower recurrence rate, lon-
ger disease-free survival, or longer overall survival in resected 
NSCLC31,33–38 and with better outcomes of first-, second-, and 
third-line pemetrexed therapy in studies of NSCLC,17–20 breast 
TABLE 2.  Univariate Survival Analyses
Median
(mo) 95% CI
Median
(mo) 95 % CI
HR  
(95 % CI) p
Performance status 0–1 (n = 178) 7.5 5.8–9.1 2 (n = 58) 4.7 3.7–7.7 0.61 (0.45–0.86) 0.004
Stage IIIB (n = 75) 6.5 5.5–7.6 IV (n = 161) 7.3 6.1–8.6 1.19 (0.83–1.51) 0.47
Sex Women (n = 110) 7.3 5.9–7.4 Men (n = 126) 6.6 5.4–9.2 0.81 (0.61–1.08) 0.16
Smoking history Never-smoker (n = 18) 7.3 2.3–12.3 Ever-smoker (n = 218) 6.9 6.1–7.6 0.79 (0.48–1.29) 0.34
Age <75 yr (n = 197) 6.9 6.0–7.8 ≥75 yr (n = 74) 7.1 4.8–9.4 1.03 (0.70–1.53) 0.87
Histology Squamous cell carcinoma (n = 62) 7.3 5.8–8.7 Adeno- and large-cell carcinoma 7.1 5.3–8.9 1.2 (0.83–1.63) 0.31
Chemotherapy Pemetrexed/carboplatin (n = 114) 7.1 6.1–8.1 Gemcitabine/carboplatin (n = 122) 6.7 5.4–8.0 0.97 (0.73–1.29) 0.83
Any second-line therapy (n = 75) 14.2 11.0–17.3 No second-line therapy (n = 161) 5.2 4.3–6.0 0.41 (0.30–0.57) <0.001
Baseline HRQoL High global QoL (n = 85) 7.8 5.5–10.0 Low global QoL (n = 151) 6.3 5.5–7.2 0.78 (0.58–1.05) 0.10
No appetite loss (n = 109) 10.1 8.4–11.9 Appetite loss (n = 127) 5.7 4.8–6.6 0.57 (0.43–0.76) <0.001
Biomarkersa Low TS (n = 120) 9.7 6.8–12.4 High TS (n = 109) 6.2 5.4–7.1 0.63 (0.46–0.84) 0.002
TTF-1 positivity (n = 111) 10.4 8.3–12.6 TTF-1 negativity (n = 117) 6.0 4.8–7.2 0.56 (0.42–0.75) <0.001
High FR (n = 101) 8.4 6.3–10.5 Low FR (n = 112) 6.5 5.7–7.2 0.85 (0.63–1.14) 0.28
High FPGS (n = 102) 7.3 5.7–9.0 Low FPGS (n = 119) 6.7 6.0–7.4 0.89 (0.66–1.19) 0.43
TTF-1 positivity and low  
TS (n = 66)
12.9 9.0–16.8 Other TTF-1 and  
TS level (n = 163)
6.3 5.5–7.1 0.71 (0.60–0.84) <0.001
aHigh was defined as ≥ median IHC score, low as < median IHC score for each marker.
CI, confidence interval; HR, hazard ratio; HRQoL, health related quality of life; TS, thymidylate synthase; TTF-1, thyroid transcription factor-1; FR-α, folate receptor-α; FPGS, 
folylpolyglutamate synthetase.
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cancer,16 and malignant pleural mesothelioma.14,15 There are, 
however, a few exceptions. In one study, TS was not a signifi-
cant prognostic factor in NSCLC,39 and there was no differ-
ence in progression-free survival or overall survival depending 
on TS level in a study of NSCLC patients who received peme-
trexed as third- or fourth-line therapy.40
Three studies have investigated whether TS predicts 
response to gemcitabine. There were no associations between 
TS level and outcomes of gemcitabine- or taxane-based che-
motherapy in a study of advanced NSCLC.18 In a study of 
pancreatic cancer, TS was associated with resistance to gem-
citabine.41 In a study of resectable NSCLC, higher response 
rates were observed among those with a low TS level. But in 
this study, gemcitabine was administered in combination with 
pemetrexed.42 A possible explanation for these observations 
and the results of our study is that high TS might be correlated 
to a high proliferation rate,33,43 and that this influences survival 
more than the differences in mechanisms of action of peme-
trexed and gemcitabine.
Results from previous studies of the prognostic value 
of TTF-1 are not uniform, but a meta-analysis as well as a 
recent article conclude that TTF-1 is an independent prog-
nostic factor in NSCLC.44,45 The associations between TTF-1 
and better outcomes of chemotherapy have been observed in 
NSCLC patients receiving pemetrexed and gemcitabine but 
not taxane therapy.18
There are less data on the role of FR and FPGS 
in NSCLC. High expression of FR-α was found to be 
a positive prognostic factor in three of four studies of 
NSCLC.20,46–48 FR-α level was not associated with out-
comes of pemetrexed therapy in a study of malignant 
pleural mesotheliomas.49 There were no significant asso-
ciations between FPGS and survival among pemetrexed-
treated NSCLC patients.50
The main strength of our study is that we have com-
pared the associations between the biomarkers and survival 
in two equally large, well-balanced cohorts that received 
either a pemetrexed or gemcitabine doublet, providing 
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FIGURE 4.  Survival depending on IHC scores in the whole study population. A, Low versus high TS. B, TTF-1 negativity versus 
positivity. C, Low versus high FR-α. D, Low versus high FPGS. The median IHC score was defined as the cutpoint for TS, FR-α, 
and FPGS. TS, thymidylate synthase; TTF-1, thyroid transcription factor-1; FR-α, folate receptor-α; FPGS, folylpolyglutamate 
synthetase; IHC, immunohistochemistry; HR, hazard ratio.
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valuable additional information to the studies that have 
included pemetrexed-treated patients only. Only three of the 
patients on the gemcitabine arm (2%) received pemetrexed 
as second-line therapy, and it is unlikely that this has influ-
enced the analyses.
There are several limitations to our study. It is a retro-
spective study and we were only able to analyze samples from 
54% of the participants in the phase III trial. Because of the 
design of the original study, we do not have data on response 
rates or progression-free survival. Thus, we have not been able 
to investigate whether any of the biomarkers predict sensitiv-
ity to either regimen, though we would expect to see differ-
ent associations between the biomarkers and overall survival 
between the two regimens if this was the case because two 
of three of the patients never received any systemic cancer 
therapy beyond the study treatment.
At the time we conducted the phase III trial (2005–
2006), the association between pemetrexed and histology 
was not known and there was less interest in subclassifica-
tion of NSCLC. IHC for subclassification of NSCLC had 
only been performed in 56% of the cases included in this 
biomarker study, and there was not enough remaining tissue 
for a comprehensive, central pathologic review (or to test for 
EGFR mutations, ALK translocations or to compare different 
antibodies for the immunohistochemical analyses). Through 
a review of the original slides (by MLI, EHS, and HS), it 
was not possible to assess the histological diagnoses with 
certainty in all cases. Thus, we have used the original histo-
logical diagnoses in this study. The suboptimal histological 
classification, in our opinion, best explains why we did not 
find the differences in TS or FR level depending on histologic 
findings reported in other studies22,34,47 though we cannot rule 
out that this can be because of the choice of antibodies. We 
have not been able to compare antibodies because of small 
tumor samples. Suboptimal histological classification can 
also very well explain why we did not find a pemetrexed/
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histology effect in our phase III trial3 or in the subcohort ana-
lyzed in the present study, which is in contrast to several other 
reports revealing that pemetrexed is mainly effective in non-
squamous NSCLC.6,8
Most of the available tumor samples were small. 
Analyses of the few surgical resection specimens in our 
cohort revealed that immune-enzyme staining was not evenly 
expressed by all tumor cells. In such relatively large tissue 
samples, there are usually areas with necrosis, differences in 
growth pattern, cell density, and mitotic activity as well as dif-
ferent levels of fixation throughout the sample. All these fac-
tors may influence the staining intensity of an antibody. Thus, 
the expression of biomarkers in biopsy samples might not be 
representative for the whole tumor or all lesions. But in rou-
tine clinical practice, only small biopsy samples are available 
from a large proportion of patients with advanced NSCLC. 
Furthermore, Herpel et al.51 found a good correlation between 
TS expression in biopsied samples and corresponding resec-
tion specimens.
Several methods for assessment of tumor TS level 
(mRNA, gene copy number, and IHC using different anti-
bodies) have been used in previous studies of TS and out-
comes of pemetrexed therapy in NSCLC.17–20 Because the 
results of most of these studies are consistent, there is no 
reason to believe that any method is superior. IHC was 
chosen in this study because it is a quick method, does not 
require fresh tumor samples, and thus, is more feasible in 
routine clinical practice. IHC is, however, limited by sub-
jectivity because it relies on the individual pathologist’s 
interpretation of the slides. In most of the cited studies 
using IHC, an H-score was calculated to assess biomarker 
expression. Because of small biopsy samples, we used a 
modified scoring system using one cutpoint for positivity 
instead of two because this resulted in far superior inter-
investigator agreement. To our knowledge, it has not been 
demonstrated that H-scores are better correlated to survival 
in NSCLC than other scoring methods for the four biomark-
ers we used. Our approach is supported by Herpel et al.51  
who found that the best correlation regarding TS level 
between biopsied samples and surgical specimens was when 
only one cutoff point for positivity was used, and a similar, 
modified IHC score was used in the study by Sun et al.18
In conclusion, we found that TS and TTF-1 and TS 
and TTF-1 combined were significant prognostic factors for 
survival in patients with advanced NSCLC who received 
either PC or GC as first-line chemotherapy. The associations 
between the TS, TTF-1, FR, and FPGS and overall survival 
were similar for both chemotherapy regimens.
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